Walter Masson

Dr. Walter Masson

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 April 2020 in Advances in Therapy
Verified
Journal Article
Open access
PDF file
WMWalter Masson
Walter Masson
MLMartín Lobo
Martín Lobo
GMGraciela Molinero
Graciela Molinero
Psoriasis is a systemic inflammatory disorder that involves complex pathogenic interactions between the innate and adaptive immune systems. Individuals with psoriasis have an increased risk of developing other chronic health diseases such cardiovascular disorders. The high incidence of cardiovascular events in the population with psoriasis could be explained by several mechanisms. The high prevalence of traditional cardiovascular risk factors and metabolic abnormalities contributes to the high cardiovascular burden in patients with psoriasis. Likewise, the presence of systemic inflammation in combination with metabolic abnormalities may act in a synergistic manner to increase cardiovascular risk in these patients. This review focused on epidemiologic and clinical evidence linking psoriasis to cardiovascular risk factors and cardiovascular disease. We described the possible pathophysiological mechanisms that justify this association and analyzed the best way to stratify the cardiovascular risk in patients with psoriasis. We also described the usefulness of the therapies frequently used in cardiovascular prevention and analyzed the impact of the specific psoriasis medication on cardiovascular risk factors or major atherosclerotic events. Knowledge of the application of different cardiovascular prevention strategies could mean an advantage in performing the difficult task of estimating cardiovascular risk and treating cardiovascular risk factors in this particular group of patients.

1 November 2020 in Annals of Hepatology
Verified
Journal Article
Open access
JAJuan Pablo Arab
Juan Pablo Arab
MDMelisa Dirchwolf
Melisa Dirchwolf
MAMario Reis Alvares-da-Silva
Mario Reis Alvares-da-Silva
FBFrancisco Barrera
Francisco Barrera
CBCarlos Benítez
Carlos Benítez
MAMarco Arrese
Marco Arrese
Non-alcoholic fatty liver disease (NAFLD) currently represents an epidemic worldwide. NAFLD is the most frequently diagnosed chronic liver disease, affecting 20-30% of the general population. Furthermore, its prevalence is predicted to increase exponentially in the next decades, concomitantly with the global epidemic of obesity, type 2 diabetes mellitus (T2DM), and sedentary lifestyle. NAFLD is a clinical syndrome that encompasses a wide spectrum of associated diseases and hepatic complications such as hepatocellular carcinoma (HCC). Moreover, this disease is believed to become the main indication for liver transplantation in the near future. Since NAFLD management represents a growing challenge for primary care physicians, the Asociación Latinoamericana para el Estudio del Hígado (ALEH) has decided to organize this Practice Guidance for the Diagnosis and Treatment of Non-Alcoholic Fatty Liver Disease, written by Latin-American specialists in different clinical areas, and destined to general practitioners, internal medicine specialists, endocrinologists, diabetologists, gastroenterologists, and hepatologists. The main purpose of this document is to improve patient care and awareness of NAFLD. The information provided in this guidance may also be useful in assisting stakeholders in the decision-making process related to NAFLD. Since new evidence is constantly emerging on different aspects of the disease, updates to this guideline will be required in future.

20 August 2021 in Cells
Verified
Journal Article
Open access
PDF file
WMWalter Masson
Walter Masson
ACAugusto Maria Lavalle Cobo
Augusto Maria Lavalle Cobo
JNJuan Patricio Nogueira
Juan Patricio Nogueira
(1) Sodium–glucose cotransporter-2 inhibitors (SGLT2-i) reduce adipose tissue and cardiovascular events in patients with type 2 diabetes (T2D). Accumulation of epicardial adipose tissue (EAT) is associated with increased cardio-metabolic risks and obstructive coronary disease events in patients with T2D. (2) We performed a systematic review and meta-analysis of SGLT2-i therapy on T2D patients, reporting data on changes in EAT after searching the PubMed/MEDLINE, Embase, Science Direct, Scopus, Google Scholar, and Cochrane databases. A random effects or fixed effects model meta-analysis was then applied. (3) Results: A total of three studies (n = 64 patients with SGLT2-i, n = 62 with standard therapy) were included in the final analysis. SGLT2 inhibitors reduced EAT (SMD: −0.82 (−1.49; −0.15); p < 0.0001). An exploratory analysis showed that HbA1c was significantly reduced with SGLT2-i use, while body mass index was not significantly reduced with this drug. (4) Conclusions: This meta-analysis suggests that the amount of EAT is significantly reduced in T2D patients with SGLT2-i treatment.

1 December 2018 in Diabetes & Metabolism
Verified
Journal Article
Closed access
WMWalter Masson
Walter Masson
MLM. Lobo
M. Lobo
DSD. Siniawski
D. Siniawski
MHM. Huerín
M. Huerín
GMG. Molinero
G. Molinero
JNJ.P. Nogueira
J.P. Nogueira

5 July 2024 in Frontiers in Cardiovascular Medicine
Verified
Journal Article
Open access
PDF file
WMWalter Masson
Walter Masson
MLMartín Lobo
Martín Lobo
JNJuan Patricio Nogueira
Juan Patricio Nogueira
ARAlfredo Matias Rodriguez-Granillo
Alfredo Matias Rodriguez-Granillo
LBLeandro Ezequiel Barbagelata
Leandro Ezequiel Barbagelata
DSDaniel Siniawski
Daniel Siniawski
Background: The anti-inflammatory effect could be one of the mechanisms by which semaglutide reduces cardiovascular risk in patients with type 2 diabetes mellitus (T2DM) and/or obesity. Determining the anti-inflammatory effect of semaglutide was the objective of this systematic review and meta-analysis.Methods: This meta-analysis was performed according to the PRISMA guidelines. A literature search was performed to detect randomised clinical trials that have quantified the effect of semaglutide on C-reactive protein (CRP) levels compared to placebo or a control group (other glucose-lowering drugs). The primary outcome was CRP index (final CRP/basal CRP). A random-effects model was used.Results: Thirteen randomised clinical trials were considered eligible (n = 26,131). Overall, semaglutide therapy was associated with lower CRP index values compared to the placebo group (SMD −0.56; 95% CI −0.69 to −0.43, I2 92%) or the control group (SMD −0.45; 95% CI −0.68 to −0.23, I2 82%).Such an association was similarly observed when different treatment regimens (subcutaneous vs. oral) or different populations (patients with or without T2DM) were analysed. The sensitivity analysis showed that the results were robust.Conclusion: The present meta-analysis demonstrated that the use of semaglutide was associated with a reduction in inflammation irrespective of the population evaluated or the treatment regimen used. These findings would explain one of the mechanisms by which semaglutide reduces cardiovascular events.Systematic Review Registration: PROSPERO [CRD42024500551].

1 July 2022 in Medicina Clinica
Verified
Journal Article
Closed access
LBLeandro Barbagelata
Leandro Barbagelata
WMWalter Masson
Walter Masson
DIDiego Iglesias
Diego Iglesias
ELEzequiel Lillo
Ezequiel Lillo
JMJuan Francisco Migone
Juan Francisco Migone
JFJoaquin Maritano Furcada
Joaquin Maritano Furcada